By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vectura Group plc 

1 Prospect West

Chippenham  Wiltshire  SN14 6FH  United Kingdom
Phone: 44-0-1249-667700 Fax: 44-0-1249-667701



Company News
Vectura (VEC.L) Release: Board Change 3/6/2017 10:26:12 AM
Vectura (VEC.L) Release: Board Change 3/6/2017 10:13:13 AM
Vectura (VEC.L) Achieves £9 Million Royalty Cap From GlaxoSmithKline (GSK) Ellipta Products 2/16/2017 9:08:54 AM
Vectura (VEC.L) Release: Seebri / Ultibro Breezhaler 2016 Sales Reach $512 Million Triggering $5 Million Milestone Receipt 1/25/2017 10:49:55 AM
Vectura (VEC.L) Release: FDA Approves IND To Support Company’s Wholly-Owned Programme VR647 In Paediatric Asthma 1/24/2017 10:23:55 AM
Vectura (VEC.L) Release: New Findings Confirm Ultibro Breezhaler Consistently More Effective Than Seretide In Reducing COPD Flare-Ups Across Different Patient Groups 9/6/2016 10:38:58 AM
Vectura (VEC.L) Release: AirFluSal Forspiro Showed Superiority At 12 Months Over Seretide Diskus In Persistence To Treatment 8/31/2016 11:41:19 AM
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016 5:52:18 AM
Lyon Manufacturing Facility Returns To Vectura (VEC.L) Upon Expiry Of Lease 7/1/2016 12:16:47 PM
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016 11:42:20 AM